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Frequency of ALK Rearrangement by FISH Testing and its
Correlation with ALK-IHC in Adenocarcinoma of Primary
Lung Origin
Samar Moatter1, Namrah Anwar1, Tariq Moatter2, Shahid Pervez1*
Abstract
Anaplastic lymphoma kinase (ALK) gene can be oncogenic either by forming fusion with other genes, amplification
of the gene or by having mutations. ALK rearrangement can either be detected by standard “fluorescence in situ
hybridization (FISH)” or “immunohistochemistry (IHC)”. Objective of this study was to record the prevalence of
ALK rearrangement in adenocarcinoma of Primary Lung origin and compare it with ALK-IHC staining. Data of
64 patients of lung adenocarcinoma from 2015-2017 was analyzed. All of the FFPE biopsies were tested for EGFR
(qPCR) followed by ALK rearrangement (by FISH and IHC) on EGFR negative samples. Out of 64 samples, 21.8%
(14) showed EGFR mutations and 14% (7/50) were positive for ALK rearrangement when checked by FISH. In IHC
testing for ALK (FISH positive) 8% (4/50) showed positivity. In conclusion ALK-FISH positive cases are higher than
other studies likely due to the relatively small sample size. FISH testing was found to be more sensitive than IHC; one
reason may be the low level of ALK. Our study warrants that currently FISH remains the gold standard for screening
of ALK gene rearrangements.
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Introduction
Detection of EGFR activating mutations and Anaplastic
Lymphoma Kinase (ALK) rearrangements has become
a standard of care for patients with adenocarcinoma
of primary lung origin. ALK protein is a member of
the Insulin receptor family of tyrosine kinases; ALK
gene was discovered in 1994 in a subset of Anaplastic
Large-Cell Lymphomas (ALCL) carrying t(2; 5) (p23;q35)
translocation (Soda et al., 2007). ALK receptor protein is
not expressed in the normal lung but gets activated by the
echinoderm microtubule-associated protein like 4(EML4)Anaplastic Lymphoma Kinase gene fusion which
occurs in approximately 3-5% of the patients with lung
adenocarcinoma (Soda et al., 2007; Chiarle et al., 2008;
Rodig et al., 2009). Rearrangements of the ALK gene are
associated with patients of younger age, non-smokers, and
adenocarcinoma with signet cells (Rodig et al., 2009).
Two main diagnostic tests being carried out to assess
ALK gene status are Fluorescent in situ hybridization
(FISH) analysis and the immunohistochemical technique
(IHC). FISH works with a breakapart probe for ALK
receptor gene analysis to determine its status in lung
adenocarcinoma (Camidge et al., 2012; Shaw et al., 2013;
Solomon et al., 2014). However FISH is technically

challenging, expensive and the required apparatus is
not readily available in routine diagnostic laboratories
along with specialized expertise (Rodig et al., 2009;
Camidge et al., 2010; Mino-Kenudson et al., 2010).
Immunohistochemical methods, on the other hand, readily
available in most Pathology labs are much cheaper and
easy to interpret. Although ALK-FISH is a Food and
Drug Administration (FDA) approved method to detect
fusion gene, a proportion of ALK-positive tumors show
no detectable rearrangements, whereas on subsequent they
were ALK IHC positive tumors and showed a remarkable
response to receiving Crizotinib treatment (Peled et al.,
2012; Sun et al., 2012; Ren et al., 2014; Shan et al., 2015).
However the lack of standardization of the IHC technique
as the primary diagnostic test has made it challenging to
make an early diagnosis of the disease and evaluate a
broader range of available treatment options. Crizotinib
has been approved by the FDA for treatment for patients
with advanced or metastatic non-small cell lung carcinoma
(Malik et al., 2014). ALK rearrangement identification is
an important procedure for lung cancers as they have a
50-60% response rate to Crizotinib and similar treatment
options such as other ALK tyrosine kinase inhibitors
leading to a better survival rate. The therapeutic options
are chosen on the basis of genetic signature EML-ALK
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translocation. Although, FISH technique is the preferred
diagnostic method, however, for a broad implementation
it is not optimal due to its technical and financial reasons,
whereas IHC techniques would be a promising diagnostic
method applicable for routine clinical practice in the near
future due to its several advantages from being easily
accessible to being more affordable and practicable.
Hence the purpose of this study was to reevaluate
previously diagnosed cases of lung adenocarcinoma tested
for ALK by FISH method using IHC testing and to further
establish the role of IHC reliable substitute for primary
screening of ALK rearrangements.

Materials and Methods
Sampling
The data of 64 patients was included who were
diagnosed as adenocarcinoma of primary lung origin
both in lung as well as in metastatic setting and tested
for EGFR mutations and ALK rearrangements in our lab
between 2015-2017. These patients were first analyzed
for EGFR mutation by a commercial Real-time PCR
kit. Then the EGFR negative samples were subjected
to ALK mutation analysis by FISH technique followed
by immunohistochemistry for ALK protein. In the case
of metastasis, only those cases were recruited where
confirmation of lung as the primary site of cancer was
established.
EGFR mutation analysis
Depending upon the size of the tissue, 2-5 sections of 5
µM thickness of FFPE specimen were cut and placed in 1.5
ml microfuge tubes. DNA extraction and multiplex PCR
was performed using Cobas EGFR mutation detection kit
and the Cobas z480 Real-time PCR instrument (Roche
Molecular Systems, Branchburg, NJ, USA); following the
standard package insert protocol. Cobas EGFR Mutation
Test uses allele-specific polymerase chain reaction (ASPCR) and can detect 43 different mutations in four exons
(18-21) of EGFR gene, including several point mutations,
deletions, and insertions.
FISH for ALK rearrangement
Paraffin sections from patients’ tumor block ranging
4-6 µm in thickness were deparaffinized in xylene before
being dehydrated with graded ethanol. The sections were
incubated in 0.2N HCl for 20min, washed and immersed

a)

in protease solution for 30min and finally fixed in 10%
buffered formalin. ALK probe cocktail (5’ 442 kb and 3’
300 kb) purchased from Abbott Diagnostics (Chicago, IL,
USA) were co-denatured at 73˚C for 7 min in Thermobrite
(Abbott Molecular, Chicago, IL, USA) and further
incubated overnight at 37˚C. Next day slides were washed
in 2X SSC/0.3% NP-40 solution twice and counterstained
with DAPI. Fluorescent signals were observed and scored
under a Nikon Eclipse 90i (Nikon Inc., Melville, NY,
USA) upright fluorescent microscope and 100 nuclei
were observed.
Immunohistochemistry for ALK
IHC was performed in automated DAKO system.
Briefly, 5 µm tumor tissue sections were deparaffinized at
60oC for 30-60 min followed by incubations in xylene and
graded ethanol. Antigens were unmasked as recommended
by the manufacturer. Primary antibody against ALK
(monoclonal mouse anti-human, CD246 from DAKO) was
incubated at room temperature for 30 mins. Subsequent
to multiple washes, tissues were blocked, and slides were
incubated with a secondary antibody linked with HRP
(DAKO, Denmark). Incubation in DAB, HRP substrate,
revealed antigenic localization. After counterstaining
with Mayer’s Haematoxylin, tissues were dehydrated and
cover-slipped. Appropriate positive and negative controls
were included in each run. The slides were assessed
independently by two histopathologists, and scoring was
done according to the reported method (To et al., 2013).

Results
EGFR mutation analysis
Out of 64 patients 14 (21.8%) came out to be positive
for EGFR mutations. The mutation test covers exon-18
to 24 of the EGFR gene. The results showed that six
patients had a deletion in exon-19. Furthermore, two
patients carried compound mutations in the following
combination S768I (Serine is replaced by Isoleucine,
exon-20) and L858R (Leucine is replaced by Arginine,
exon-21) and other showed combination T790M (change
from Threonine to Methionine, exon- 20) and G719X
(exon-18). Six patients were positive for point mutation
L858R in exon-21.
ALK analysis by FISH
Breakapart probes labeled with red and green

b)

Figure 1. A Representative Image of ALK Negative (a) and Positive (b) Lung Adenocarcinoma. Separated Red and
Green signals indicate ALK gene rearrangement
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Figure 2. Bronchial Biopsy Showing Foci of Moderately
Differentiated Adenocarcinoma of Primary Lung Origin.
Note diffuse cytoplasmic staining with ALK Protein
fluorochromes were used to analyze ALK rearrangement
at 2p23. The red probe was telomeric probe (3’) and the
green probe was centromeric probe (5’). Intact gene would
exhibit fused signal of yellow color (Figure 1a), else the
signal would split in to green and red in case of inversion
of the region (Figure 1b), and either of the signals would
be lost if a deletion occurs. A total of 100 nuclei were
observed and a rearrangement was considered positive if
observed in more than 15% of the nuclei and signals were
at least two diameters apart. Out of 50 patients, 7 (14%)
patients were found to have ALK gene rearrangements.
ALK by IHC
ALK was checked on all the samples which were
FISH positive along with a subset of negative samples.
According to the published criteria, IHC scores of 0
and 1+ were chosen as negative and scores of 2+ or 3+
as positive. Out of seven samples 4 showed diffused
cytoplasmic staining and one sample came out to be
weak positive (+1) which was considered as negative and
other two samples were negative for ALK rearrangement
staining (Figure 2).

Discussion
This study was done to determine the presence of
EGFR mutations with ALK mutations and association of
FISH and IHC for ALK testing diagnostically in Pakistani
population of Lung Adenocarcinoma which is a common
type of lung cancer and first line of treatment includes
the platinum based therapy chemotherapy (Ellison et al.,
2013). However, some patients harboring mutations are
eligible for the TKIs which provide an advance treatment.
EGFR is the most commonly mutated gene in such cases
which accounts for like 60% of the overall cases. Almost
90% of these mutations are either in-frame deletions of
exon-19 which removes the amino acids from 747-750
(LREA) or single nucleotide substitution of thymine to
guanine resulting in change of arginine from leucine at 858
position of exon-21 (Shigematsu et al., 2005; Ellison et
al., 2013). However, according to different published data,

half of the cases tend to progress towards a second-site
mutation in EGFR kinase domain and more than 90%
is the change of thymine to cytosine at 2639 position in
exon 20. (Kwak et al., 2005; Balak et al., 2006; Kosaka et
al., 2006). Our study showed the similar results to these
studies in EGFR mutational analysis which provided the
insight into the eligibility of patients for TKIs. Compound
mutations were also observed which showed the increased
resistance towards the TKIs.
In 2007, Soda et al., (2007) reported a fusion gene
consisted of portions of EML4 (N terminal segment)
and ALK( kinase domain) as a result of small inversion
within chromosome 2p. The EML4-ALK translocation
represents a new subgroup of lung adenocarcinoma
patients who respond positively to ALK inhibitors. Recent
studies suggest that presence of EML4-ALK fusion varies
from 3-6% depending on the factors like ethnicity and
detection methods (Takeuchi et al., 2008; Takeuchi et al.,
2009). According to different studies genetic alterations
in EGFR, KRAS, and ALK do not co-exist (Gainor et
al., 2013). The results of this study concord with the
published reports showing that the mutations of EGFR
and ALK are mutually exclusive. Moreover, in our study,
the overall ALK positivity was 14% which is higher than
the reported data where, limited sample size remained
a constraint. As ALK mutations mostly consists of
intrachormosomal deletion and inversion so the diagnosis
for ALK rearrangement requires FISH, RT-qPCR and
ISH where FISH being the gold standard in diagnostics
(Gainor et al., 2013).
Both techniques have pros and cons and recent
publications in order to find the association of both
the techniques in ALK detection have discussed the
discordances (Boland et al., 2009). FISH has been
approved by FDA as the method of choice for patient
selection in clinical trials. The breakapart probe allows
detection of rearrangements without the specificity of
breakpoint. In addition, nonspecific signal separation
could not be attributed to cells without rearrangement
which increases the possibility of false results and
intraobserver variability. Moreover, FISH requires
specialized laboratory equipment and techniques,
expert interpretation, relatively high costs, and a longer
turnaround time and fluorescent signals rapidly fades
away with time (Camidge et al., 2010). An alternative
diagnostic method to FISH is IHC, which recently has
been studied extensively for its usability in routine testing.
The efficacy of IHC detection depends on various factors
like tissue preparation, scoring system (H-score), type and
affinity of antibody and the sensitivity of detection system.
IHC was shown to be specific but not sensitive in earlier
studies which could be attributed to the low transcriptional
activity or instability of EML4 in cells (Martelli et al.,
2009; Murakami et al., 2012). In a study conducted by
Sholl et al. found one out of 15 ALK-positive specimens
tested by FISH method was falsely negative and two were
false positives after being reanalyzed using IHC, further
highlighting the importance of this testing technique (Sholl
et al., 2013). In our study four of the FISH positive ALK
samples showed strong cytoplasmic staining in IHC and
Asian Pacific Journal of Cancer Prevention, Vol 19
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three positive samples in FISH came out to be negative
in IHC. These results were in agreement with some of the
studies reported (Eunhee et al., 2011; Paik et al., 2011;
McLeer-Florin et al., 2012).
To the list of our knowledge this is the first study
from Pakistan reporting frequency of ALK rearrangement
in adenocarcinoma of Primary Lung origin as well as
correlation of FISH results with ALK IHC. Currently,
the false negative results and less sensitivity do not
make IHC plausible as primary screening technique.
This study however, had some limitations which include
small sample size and IHC testing with only one clone
of ALK protein.
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